In a nutshell This study compared the effectiveness of common immuno-chemotherapy (ICT) treatments for advanced follicular lymphoma (FL) for front-line therapy. The study showed that obinutuzumab (Gazyva; G) combined with bendamustine (Treanda; Benda) (G-Benda-G regimen) had the best survival without cancer worsening in patients with advanced...
Read More
In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...
Read More
In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...
Read More
In a nutshell This study compared the long-term safety and effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in high-risk patients with advanced classical Hodgkin lymphoma (cHL). The data showed that the A+AVD...
Read More
In a nutshell This study aimed to investigate if rituximab (Rituxan), bendamustine (Treanda), and mitoxantrone (Novantrone) or R-BM followed by rituximab consolidation was a safe and effective treatment in older patients with follicular lymphoma (FL). The authors concluded that this treatment provided durable responses and was well tolerated in...
Read More
In a nutshell This study investigated whether lenalidomide maintenance therapy after intensive chemoimmunotherapy and first-line autologous hematopoietic stem-cell transplantation (AHSCT) improved the outcomes of patients with mantle cell lymphoma (MCL). The data showed that lenalidomide maintenance after AHSCT improved the survival without...
Read More
In a nutshell The study evaluated the impact of consolidation radiotherapy (cRT) on patients with advanced Hodgkin lymphoma (HL) who had large nodal mass (LNM) and currently in complete metabolic response (CMR) after receiving ABVD chemotherapy. The authors found that cRT could be safely avoided in such patients. Some background CMR defines...
Read More
In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...
Read More
In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...
Read More
In a nutshell This trial is looking to assess the effectiveness of ME-401 for relapsed follicular lymphoma (FL) after the failure of two or more therapies. The main outcome to be measured in this trial is the percentage of patients whose cancer shrinks or disappears after treatment. The details FL is a type of non-Hodgkin lymphoma....
Read More
In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...
Read More
In a nutshell This study compared ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations to understand which is more effective long term for patients with advanced classical Hodgkin lymphoma (HL). The authors concluded...
Read More
